{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:52:11Z","timestamp":1775217131337,"version":"3.50.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["National Natural Science Foundation of China"],"award-info":[{"award-number":["National Natural Science Foundation of China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00705-026-06569-6","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:13:38Z","timestamp":1773152018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Research progress of nucleocapsid protein of novel coronavirus: structure, function and targeted therapy"],"prefix":"10.1007","volume":"171","author":[{"given":"Xie","family":"Moyue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Dongang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"6569_CR1","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.20546\/ijcmas.2020.904.372","volume":"9","author":"TR Suthar","year":"2020","unstructured":"Suthar TR, Gaikwad ST, Suthar AD (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus Disease-2019 (COVID-19): A review. Int J Curr Microbiol Appl Sci 9:3201\u20133208","journal-title":"Int J Curr Microbiol Appl Sci"},{"key":"6569_CR2","doi-asserted-by":"crossref","unstructured":"Synowiec A, Szczepanski A, Barreto-Duran E, Lie LK, Pyrc K (2021) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systemic infection. Clin Microbiol Rev 34","DOI":"10.1128\/CMR.00133-20"},{"key":"6569_CR3","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli AM et al (2023) SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 21:162\u2013177","journal-title":"Nat Rev Microbiol"},{"key":"6569_CR4","doi-asserted-by":"publisher","first-page":"115772","DOI":"10.1016\/j.ejmech.2023.115772","volume":"260","author":"X Li","year":"2023","unstructured":"Li X, Song Y (2023) Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. Eur J Med Chem 260:115772","journal-title":"Eur J Med Chem"},{"key":"6569_CR5","doi-asserted-by":"crossref","unstructured":"Alsafi RT (2022) Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. Can J Infect Dis Med Microbiol 1156273 (2022)","DOI":"10.1155\/2022\/1156273"},{"key":"6569_CR6","doi-asserted-by":"publisher","first-page":"e2282","DOI":"10.1002\/rmv.2282","volume":"32","author":"MM Kesheh","year":"2022","unstructured":"Kesheh MM, Hosseini P, Soltani S, Zandi M (2022) An overview on the seven pathogenic human coronaviruses. Rev Med Virol 32:e2282","journal-title":"Rev Med Virol"},{"key":"6569_CR7","doi-asserted-by":"crossref","unstructured":"Mohapatra RK, Kandi V, Verma S, Dhama K (2022) Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective. Chembiochem 23, e202200059","DOI":"10.1002\/cbic.202200059"},{"key":"6569_CR8","unstructured":"Qurashi YMAA et al (2024) Molecular epidemiology of Omicron CH.1.1 lineage: genomic and phenotypic data perspective. Cureus"},{"key":"6569_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2020.09.131","volume":"538","author":"L Zinzula","year":"2021","unstructured":"Zinzula L et al (2021) High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2. Biochem Biophys Res Commun 538:54\u201362","journal-title":"Biochem Biophys Res Commun"},{"key":"6569_CR10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","volume":"183","author":"H Yao","year":"2020","unstructured":"Yao H et al (2020) Molecular architecture of the SARS-CoV-2 virus. Cell 183:730\u2013738e713","journal-title":"Cell"},{"key":"6569_CR11","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3390\/pharmaceutics13111759","volume":"13","author":"EM Saied","year":"2021","unstructured":"Saied EM et al (2021) A comprehensive review about the molecular structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): insights into natural products against COVID-19. Pharmaceutics 13:1759","journal-title":"Pharmaceutics"},{"key":"6569_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin D et al (2020) Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587:657\u2013662","journal-title":"Nature"},{"key":"6569_CR13","doi-asserted-by":"publisher","first-page":"135201","DOI":"10.1016\/j.ijbiomac.2024.135201","volume":"279","author":"YA El-Maradny","year":"2024","unstructured":"El-Maradny YA et al (2024) Unraveling the role of the nucleocapsid protein in SARS-CoV-2 pathogenesis: from viral life cycle to vaccine development. Int J Biol Macromol 279:135201","journal-title":"Int J Biol Macromol"},{"key":"6569_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12104-021-10009-8","volume":"15","author":"M Schiavina","year":"2021","unstructured":"Schiavina M, Pontoriero L, Uversky VN, Felli IC, Pierattelli R (2021) The highly flexible disordered regions of the SARS-CoV-2 nucleocapsid N protein within the 1\u2013248 residue construct: sequence-specific resonance assignments through NMR. Biomol NMR Assignments 15:219\u2013227","journal-title":"Biomol NMR Assignments"},{"key":"6569_CR15","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3390\/v6082991","volume":"6","author":"R McBride","year":"2014","unstructured":"McBride R, van Zyl M, Fielding BC (2014) The coronavirus nucleocapsid is a multifunctional protein. Viruses 6:2991\u20133018","journal-title":"Viruses"},{"key":"6569_CR16","doi-asserted-by":"publisher","first-page":"10543","DOI":"10.1021\/jacs.2c03320","volume":"144","author":"S Sarkar","year":"2022","unstructured":"Sarkar S et al (2022) Atomic-Resolution structure of SARS-CoV-2 nucleocapsid protein N-Terminal domain. J Am Chem Soc 144:10543\u201310555","journal-title":"J Am Chem Soc"},{"key":"6569_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41564-021-00958-0","volume":"6","author":"J Baggen","year":"2021","unstructured":"Baggen J, Vanstreels E, Jansen S, Daelemans D (2021) Cellular host factors for SARS-CoV-2 infection. Nat Microbiol 6:1219\u20131232","journal-title":"Nat Microbiol"},{"key":"6569_CR18","doi-asserted-by":"publisher","first-page":"102523","DOI":"10.1016\/j.isci.2021.102523","volume":"24","author":"H Zhao","year":"2021","unstructured":"Zhao H et al (2021) Energetic and structural features of SARS-CoV-2\u00a0N-protein co-assemblies with nucleic acids. iScience 24:102523\u2013102523","journal-title":"iScience"},{"key":"6569_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/v13061115","volume":"13","author":"Z Bai","year":"2021","unstructured":"Bai Z, Cao Y, Liu W, Li J (2021) The SARS-CoV-2 nucleocapsid protein and its role in viral Structure, biological Functions, and a potential target for drug or vaccine mitigation. Viruses 13:1115","journal-title":"Viruses"},{"key":"6569_CR20","doi-asserted-by":"publisher","first-page":"e105938","DOI":"10.15252\/embj.2020105938","volume":"39","author":"Y Peng","year":"2020","unstructured":"Peng Y et al (2020) Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. EMBO J 39:e105938","journal-title":"EMBO J"},{"key":"6569_CR21","doi-asserted-by":"crossref","unstructured":"Wu W, Cheng Y, Zhou H, Sun C, Zhang S (2023) The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virol J 20","DOI":"10.1186\/s12985-023-01968-6"},{"key":"6569_CR22","doi-asserted-by":"publisher","first-page":"e1009100","DOI":"10.1371\/journal.ppat.1009100","volume":"16","author":"DC Dinesh","year":"2020","unstructured":"Dinesh DC et al (2020) Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein. PLoS Pathog 16:e1009100","journal-title":"PLoS Pathog"},{"key":"6569_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.apsb.2020.04.009","volume":"10","author":"S Kang","year":"2020","unstructured":"Kang S et al (2020) Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sinica B 10:1228\u20131238","journal-title":"Acta Pharm Sinica B"},{"key":"6569_CR24","doi-asserted-by":"publisher","first-page":"107834","DOI":"10.1016\/j.jbc.2024.107834","volume":"300","author":"PR Bezerra","year":"2024","unstructured":"Bezerra PR, Almeida FC (2024) L. Structural basis for the participation of the SARS-CoV-2 nucleocapsid protein in the template switch mechanism and genomic RNA reorganization. J Biol Chem 300:107834","journal-title":"J Biol Chem"},{"key":"6569_CR25","doi-asserted-by":"crossref","unstructured":"Zhou R, Zeng R, von Brunn A, Lei J (2020) Structural characterization of the C-terminal domain of SARS-CoV-2 nucleocapsid protein. Mol Biomed 1","DOI":"10.1186\/s43556-020-00001-4"},{"key":"6569_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbrc.2020.04.136","volume":"527","author":"W Zeng","year":"2020","unstructured":"Zeng W et al (2020) Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun 527:618\u2013623","journal-title":"Biochem Biophys Res Commun"},{"key":"6569_CR27","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s41467-021-21953-3","volume":"12","author":"J Cubuk","year":"2021","unstructured":"Cubuk J et al (2021) The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat Commun 12:1936","journal-title":"Nat Commun"},{"key":"6569_CR28","doi-asserted-by":"crossref","unstructured":"Han Y et al (2024) SARS-CoV-2\u00a0N protein coordinates viral particle assembly through multiple domains. J Virol, e0103624","DOI":"10.1128\/jvi.01036-24"},{"key":"6569_CR29","doi-asserted-by":"publisher","first-page":"151594","DOI":"10.1016\/j.bbrc.2025.151594","volume":"756","author":"L Gu","year":"2025","unstructured":"Gu L et al (2025) Targeting the liquid-liquid phase separation of nucleocapsid broadly inhibits the replication of SARS-CoV-2 strains. Biochem Biophys Res Commun 756:151594","journal-title":"Biochem Biophys Res Commun"},{"key":"6569_CR30","doi-asserted-by":"publisher","first-page":"101677","DOI":"10.1016\/j.jbc.2022.101677","volume":"298","author":"SM Cascarina","year":"2022","unstructured":"Cascarina SM, Ross ED (2022) Phase separation by the SARS-CoV-2 nucleocapsid protein: consensus and open questions. J Biol Chem 298:101677","journal-title":"J Biol Chem"},{"key":"6569_CR31","doi-asserted-by":"publisher","first-page":"102681","DOI":"10.1016\/j.isci.2021.102681","volume":"24","author":"C Wu","year":"2021","unstructured":"Wu C et al (2021) Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain. iScience 24:102681","journal-title":"iScience"},{"key":"6569_CR32","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.csbj.2020.07.005","volume":"18","author":"S Barik","year":"2020","unstructured":"Barik S (2020) Genus-specific pattern of intrinsically disordered central regions in the nucleocapsid protein of coronaviruses. Comput Struct Biotechnol J 18:1884\u20131890","journal-title":"Comput Struct Biotechnol J"},{"key":"6569_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijmmb.2022.02.005","volume":"40","author":"V Ravi","year":"2022","unstructured":"Ravi V, Saxena S, Panda PS (2022) Basic virology of SARS-CoV 2. Indian J Med Microbiol 40:182\u2013186","journal-title":"Indian J Med Microbiol"},{"key":"6569_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41467-020-20768-y","volume":"12","author":"S Lu","year":"2021","unstructured":"Lu S et al (2021) The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein. Nat Commun 12:502","journal-title":"Nat Commun"},{"key":"6569_CR35","doi-asserted-by":"publisher","first-page":"e3001425","DOI":"10.1371\/journal.pbio.3001425","volume":"19","author":"A Jack","year":"2021","unstructured":"Jack A et al (2021) SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA. PLoS Biol 19:e3001425","journal-title":"PLoS Biol"},{"key":"6569_CR36","doi-asserted-by":"publisher","first-page":"107354","DOI":"10.1016\/j.jbc.2024.107354","volume":"300","author":"H Stuwe","year":"2024","unstructured":"Stuwe H et al (2024) Phosphorylation in the Ser\/Arg-rich region of the nucleocapsid of SARS-CoV-2 regulates phase separation by inhibiting self-association of a distant helix. J Biol Chem 300:107354","journal-title":"J Biol Chem"},{"key":"6569_CR37","doi-asserted-by":"crossref","unstructured":"Nguyen A et al (2024) Modulation of biophysical properties of nucleocapsid protein in the mutant spectrum of SARS-CoV-2. eLife 13, RP94836","DOI":"10.7554\/eLife.94836"},{"key":"6569_CR38","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.abl6184","volume":"374","author":"AM Syed","year":"2021","unstructured":"Syed AM et al (2021) Rapid assessment of SARS-CoV-2-evolved variants using virus-like particles. Science 374:1626\u20131632","journal-title":"Science"},{"key":"6569_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41590-024-02051-0","volume":"26","author":"J Tian","year":"2025","unstructured":"Tian J et al (2025) T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots. Nat Immunol 26:265\u2013278","journal-title":"Nat Immunol"},{"key":"6569_CR40","doi-asserted-by":"crossref","unstructured":"Zhao H et al (2024) Assembly of SARS-CoV-2 nucleocapsid protein with nucleic acid. Nucleic Acids Res","DOI":"10.1101\/2023.11.22.568361"},{"key":"6569_CR41","doi-asserted-by":"publisher","first-page":"e0092624","DOI":"10.1128\/jvi.00926-24","volume":"98","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al (2024) Unraveling the assembly mechanism of SADS-CoV virus nucleocapsid protein: insights from RNA binding, dimerization, and epitope diversity profiling. J Virol 98:e0092624","journal-title":"J Virol"},{"key":"6569_CR42","doi-asserted-by":"crossref","unstructured":"Zhang Y et al (2021) The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-\u0399. Proc Natl Acad Sci USA 118","DOI":"10.1073\/pnas.2024202118"},{"key":"6569_CR43","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41422-021-00573-y","volume":"31","author":"R Zhu","year":"2021","unstructured":"Zhu R et al (2021) Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple Immunomodulatory mechanisms. Cell Res 31:1244\u20131262","journal-title":"Cell Res"},{"key":"6569_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12026-021-09224-1","volume":"69","author":"L Wenzhong","year":"2021","unstructured":"Wenzhong L, Hualan L (2021) COVID-19: the CaMKII-like system of S protein drives membrane fusion and induces syncytial multinucleated giant cells. Immunol Res 69:496\u2013519","journal-title":"Immunol Res"},{"key":"6569_CR45","doi-asserted-by":"crossref","unstructured":"Wang J, Shi C, Xu Q, Yin H (2021) SARS-CoV-2 nucleocapsid protein undergoes liquid\u2013liquid phase separation into stress granules through its N-terminal intrinsically disordered region. Cell Discovery 7","DOI":"10.1038\/s41421-020-00240-3"},{"key":"6569_CR46","doi-asserted-by":"publisher","first-page":"eadg6473","DOI":"10.1126\/sciadv.adg6473","volume":"9","author":"H Zhao","year":"2023","unstructured":"Zhao H et al (2023) A conserved oligomerization domain in the disordered linker of coronavirus nucleocapsid proteins. Sci Adv 9:eadg6473","journal-title":"Sci Adv"},{"key":"6569_CR47","doi-asserted-by":"crossref","unstructured":"Cheng N et al (2023) Protein post-translational modification in SARS-CoV-2 and host interaction. Front Immunol 13","DOI":"10.3389\/fimmu.2022.1068449"},{"key":"6569_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/jb\/mvad061","volume":"174","author":"M Okuwaki","year":"2023","unstructured":"Okuwaki M et al (2023) The stability of NPM1 oligomers regulated by acidic disordered regions controls the quality of liquid droplets. J Biochem 174:461\u2013476","journal-title":"J Biochem"},{"key":"6569_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang H, Rao Z (2021) Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol 19:685\u2013700","journal-title":"Nat Rev Microbiol"},{"key":"6569_CR50","doi-asserted-by":"crossref","unstructured":"Liu J et al (2024) SARS-CoV-2 nucleocapsid protein antagonizes GADD34-Mediated innate immune pathway through atypical foci. Molecules 29","DOI":"10.3390\/molecules29204792"},{"key":"6569_CR51","doi-asserted-by":"publisher","first-page":"e2431","DOI":"10.1002\/rmv.2431","volume":"33","author":"F Maghsood","year":"2023","unstructured":"Maghsood F et al (2023) SARS-CoV-2 nucleocapsid: biological functions and implication for disease diagnosis and vaccine design. Rev Med Virol 33:e2431","journal-title":"Rev Med Virol"},{"key":"6569_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41421-020-00208-3","volume":"6","author":"J Mu","year":"2020","unstructured":"Mu J et al (2020) SARS-CoV-2\u00a0N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discovery 6:65","journal-title":"Cell Discovery"},{"key":"6569_CR53","doi-asserted-by":"publisher","first-page":"e01516","DOI":"10.1128\/jvi.01516-24","volume":"99","author":"Z Cai","year":"2025","unstructured":"Cai Z et al (2025) SARS-CoV-2 S protein disrupts the formation of ISGF3 complex through conserved S2 subunit to antagonize type I interferon response. J Virol 99:e01516\u201301524","journal-title":"J Virol"},{"key":"6569_CR54","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jaci.2019.03.016","volume":"143","author":"O Scott","year":"2019","unstructured":"Scott O, Roifman CM (2019) NF-kappaB pathway and the goldilocks principle: lessons from human disorders of immunity and inflammation. J Allergy Clin Immunol 143:1688\u20131701","journal-title":"J Allergy Clin Immunol"},{"key":"6569_CR55","doi-asserted-by":"crossref","unstructured":"Yu H, Guan F, Miller H, Lei J, Liu C (2023) The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development. Emerg Microbes Infections 12","DOI":"10.1080\/22221751.2022.2164219"},{"key":"6569_CR56","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-021-25015-6","volume":"12","author":"P Pan","year":"2021","unstructured":"Pan P et al (2021) SARS-CoV-2\u00a0N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun 12:4664","journal-title":"Nat Commun"},{"key":"6569_CR57","doi-asserted-by":"publisher","first-page":"e3003115","DOI":"10.1371\/journal.pbio.3003115","volume":"23","author":"HC Kubinski","year":"2025","unstructured":"Kubinski HC et al (2025) Variant mutation G215C in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation. PLoS Biol 23:e3003115","journal-title":"PLoS Biol"},{"key":"6569_CR58","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12192-023-01379-0","volume":"28","author":"RS Hamad","year":"2023","unstructured":"Hamad RS et al (2023) SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway. Cell Stress Chaperones 28:657\u2013673","journal-title":"Cell Stress Chaperones"},{"key":"6569_CR59","doi-asserted-by":"publisher","first-page":"105115","DOI":"10.1016\/j.antiviral.2021.105115","volume":"192","author":"T Kashyap","year":"2021","unstructured":"Kashyap T et al (2021) Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. Antiviral Res 192:105115","journal-title":"Antiviral Res"},{"key":"6569_CR60","doi-asserted-by":"crossref","unstructured":"Nabti I et al (2022) The ubiquitous microtubule-associated protein 4 (MAP4) controls organelle distribution by regulating the activity of the kinesin motor. Proceedings of the National Academy of Sciences 119","DOI":"10.1073\/pnas.2206677119"},{"key":"6569_CR61","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3390\/v14102089","volume":"14","author":"S Li","year":"2022","unstructured":"Li S, Zandi R (2022) Biophysical modeling of SARS-CoV-2 assembly: genome condensation and budding. Viruses 14:2089","journal-title":"Viruses"},{"key":"6569_CR62","doi-asserted-by":"crossref","unstructured":"Jiao L et al (2023) Ribosome biogenesis in disease: new players and therapeutic targets. Signal Transduct Target Therapy 8","DOI":"10.1038\/s41392-022-01285-4"},{"key":"6569_CR63","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1038\/s44318-025-00449-6","volume":"44","author":"D Hayat","year":"2025","unstructured":"Hayat D et al (2025) Inhibitors of eIF1A-ribosome interaction unveil uORF-dependent regulation of translation initiation and antitumor and antiviral effects. EMBO J 44:3853\u20133871","journal-title":"EMBO J"},{"key":"6569_CR64","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.scib.2022.10.021","volume":"67","author":"X Luan","year":"2022","unstructured":"Luan X et al (2022) Antiviral drug design based on structural insights into the N-terminal domain and C-terminal domain of the SARS-CoV-2 nucleocapsid protein. Sci Bull (Beijing) 67:2327\u20132335","journal-title":"Sci Bull (Beijing)"},{"key":"6569_CR65","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.apsb.2024.03.009","volume":"14","author":"X Wei","year":"2024","unstructured":"Wei X et al (2024) Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein. Acta Pharm Sinica B 14:2505\u20132519","journal-title":"Acta Pharm Sinica B"},{"key":"6569_CR66","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12866-025-03847-2","volume":"25","author":"R Luo","year":"2025","unstructured":"Luo R et al (2025) Taurultam shows antiviral activity against SARS-CoV-2 and influenza virus. BMC Microbiol 25:292","journal-title":"BMC Microbiol"},{"key":"6569_CR67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10529-025-03576-6","volume":"47","author":"B Yu","year":"2025","unstructured":"Yu B et al (2025) Construction and immunogenicity analysis of a Recombinant baculovirus targeting the N protein of SARS-CoV-2. Biotechnol Lett 47:42","journal-title":"Biotechnol Lett"},{"key":"6569_CR68","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1038\/s41467-021-23036-9","volume":"12","author":"S Kang","year":"2021","unstructured":"Kang S et al (2021) A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. Nat Commun 12:2697","journal-title":"Nat Commun"},{"key":"6569_CR69","unstructured":"Derde L (2025) Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02735707?cond=ceftriaxone&draw=3."},{"key":"6569_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s41182-025-00756-y","volume":"53","author":"MM Mutua","year":"2025","unstructured":"Mutua MM et al (2025) Development of monoclonal antibodies against SARS-CoV-2 nucleocapsid protein for COVID-19 antigen detection. Trop Med Health 53:69","journal-title":"Trop Med Health"},{"key":"6569_CR71","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41422-020-00408-2","volume":"30","author":"H Chen","year":"2020","unstructured":"Chen H et al (2020) Liquid\u2013liquid phase separation by SARS-CoV-2 nucleocapsid protein and RNA. Cell Res 30:1143\u20131145","journal-title":"Cell Res"},{"key":"6569_CR72","doi-asserted-by":"publisher","first-page":"e1012097","DOI":"10.1371\/journal.ppat.1012097","volume":"20","author":"W Xue","year":"2024","unstructured":"Xue W et al (2024) Coronavirus nucleocapsid protein enhances the binding of p-PKCalpha to RACK1: implications for Inhibition of nucleocytoplasmic trafficking and suppression of the innate immune response. PLoS Pathog 20:e1012097","journal-title":"PLoS Pathog"},{"key":"6569_CR73","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12985-025-02658-1","volume":"22","author":"AD L\u00f3pez-Mu\u00f1oz","year":"2025","unstructured":"L\u00f3pez-Mu\u00f1oz AD, Yewdell JW (2025) Chemokines simultaneously bind SARS-CoV-2 nucleocapsid protein RNA-binding and dimerization domains. Virol J 22:77","journal-title":"Virol J"},{"key":"6569_CR74","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1038\/s41467-024-51192-1","volume":"15","author":"Y-W Luo","year":"2024","unstructured":"Luo Y-W et al (2024) SARS-CoV-2\u00a0N protein-induced Dicer, XPO5, SRSF3, and hnRNPA3 downregulation causes pneumonia. Nat Commun 15:6964","journal-title":"Nat Commun"},{"key":"6569_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai L, Gao GF (2021) Viral targets for vaccines against COVID-19. Nat Rev Immunol 21:73\u201382. https:\/\/doi.org\/10.1038\/s41577-020-00480-0","journal-title":"Nat Rev Immunol"},{"key":"6569_CR76","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403\u2013416","journal-title":"N Engl J Med"},{"key":"6569_CR77","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603\u20132615","journal-title":"N Engl J Med"},{"key":"6569_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis 21:181\u2013192","journal-title":"Lancet Infect Dis"},{"key":"6569_CR79","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech C et al (2020) Phase 1\u20132 trial of a SARS-CoV-2 Recombinant Spike protein nanoparticle vaccine. N Engl J Med 383:2320\u20132332","journal-title":"N Engl J Med"},{"key":"6569_CR80","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","volume":"386","author":"L Dai","year":"2022","unstructured":"Dai L et al (2022) Efficacy and safety of the RBD-Dimer-Based Covid-19 vaccine ZF2001 in adults. N Engl J Med 386:2097\u20132111","journal-title":"N Engl J Med"},{"key":"6569_CR81","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC et al (2020) Safety, tolerability, and immunogenicity of a Recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395:1845\u20131854","journal-title":"Lancet"},{"key":"6569_CR82","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov DY et al (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396:887\u2013897","journal-title":"Lancet"},{"key":"6569_CR83","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM et al (2020) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396:467\u2013478","journal-title":"Lancet"},{"key":"6569_CR84","unstructured":"COVID-19 vaccine tracker and landscape, https:\/\/www.who.int\/teams\/blueprint\/covid-19\/covid-19-vaccine-tracker-and-landscape. (2025)"},{"key":"6569_CR85","doi-asserted-by":"publisher","first-page":"963689723118461","DOI":"10.1177\/09636897231184611","volume":"32","author":"Y Fang","year":"2023","unstructured":"Fang Y et al (2023) Mechanisms of potential therapeutic utilization of mesenchymal stem cells in COVID-19 treatment. Cell Transpl 32:9636897231184611","journal-title":"Cell Transpl"},{"key":"6569_CR86","doi-asserted-by":"publisher","first-page":"695362","DOI":"10.3389\/fcell.2021.695362","volume":"9","author":"A Babajani","year":"2021","unstructured":"Babajani A, Hosseini-Monfared P, Abbaspour S, Jamshidi E, Niknejad H (2021) Targeted mitochondrial therapy with Over-Expressed MAVS protein from mesenchymal stem cells: A new therapeutic approach for COVID-19. Front Cell Dev Biol 9:695362","journal-title":"Front Cell Dev Biol"},{"key":"6569_CR87","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12920-022-01243-7","volume":"15","author":"C Li","year":"2022","unstructured":"Li C et al (2022) SARS-COV-2 as potential MicroRNA sponge in COVID-19 patients. BMC Med Genomics 15:94","journal-title":"BMC Med Genomics"},{"key":"6569_CR88","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.ymthe.2021.05.005","volume":"29","author":"Y Teng","year":"2021","unstructured":"Teng Y et al (2021) Plant-derived Exosomal MicroRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12. Mol Ther 29:2424\u20132440","journal-title":"Mol Ther"},{"key":"6569_CR89","doi-asserted-by":"publisher","first-page":"113008","DOI":"10.1016\/j.fct.2022.113008","volume":"164","author":"S Seneff","year":"2022","unstructured":"Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA (2022) Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol 164:113008","journal-title":"Food Chem Toxicol"},{"key":"6569_CR90","doi-asserted-by":"publisher","first-page":"2191577","DOI":"10.1080\/21645515.2023.2191577","volume":"19","author":"T Yadav","year":"2023","unstructured":"Yadav T, Kumar S, Mishra G, Saxena SK (2023) Tracking the COVID-19 vaccines: the global landscape. Hum Vaccin Immunother 19:2191577","journal-title":"Hum Vaccin Immunother"},{"key":"6569_CR91","doi-asserted-by":"publisher","first-page":"2410574","DOI":"10.1080\/21645515.2024.2410574","volume":"20","author":"U Klinkardt","year":"2024","unstructured":"Klinkardt U et al (2024) A novel Orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity. Hum Vaccin Immunother 20:2410574","journal-title":"Hum Vaccin Immunother"},{"key":"6569_CR92","doi-asserted-by":"publisher","first-page":"106288","DOI":"10.1016\/j.jinf.2024.106288","volume":"89","author":"SO Rabdano","year":"2024","unstructured":"Rabdano SO et al (2024) N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial. J Infect 89:106288","journal-title":"J Infect"},{"key":"6569_CR93","doi-asserted-by":"publisher","first-page":"1188605","DOI":"10.3389\/fimmu.2023.1188605","volume":"14","author":"C Primard","year":"2023","unstructured":"Primard C et al (2023) OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. Front Immunol 14:1188605","journal-title":"Front Immunol"},{"key":"6569_CR94","doi-asserted-by":"publisher","first-page":"eabq1945","DOI":"10.1126\/scitranslmed.abq1945","volume":"14","author":"RL Hajnik","year":"2022","unstructured":"Hajnik RL et al (2022) Dual Spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and delta variants in preclinical models. Sci Transl Med 14:eabq1945","journal-title":"Sci Transl Med"},{"key":"6569_CR95","unstructured":"clinicaltrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT05696067 (2025)"},{"key":"6569_CR96","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","volume":"3","author":"JY Ahn","year":"2022","unstructured":"Ahn JY et al (2022) Safety and immunogenicity of two Recombinant DNA COVID-19 vaccines containing the coding regions of the Spike or Spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe 3:e173\u2013e183","journal-title":"Lancet Microbe"},{"key":"6569_CR97","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41467-023-44502-6","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren J et al (2024) TRIM28-mediated nucleocapsid protein sumoylation enhances SARS-CoV-2 virulence. Nat Commun 15:244","journal-title":"Nat Commun"},{"key":"6569_CR98","unstructured":"National Health Commission of China & State Administration of Traditional Chinese Medicine. (2023). Diagnosis and treatment protocol for COVID-19 infection (Trial Version 10)., http:\/\/www.nhc.gov.cn"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-026-06569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-026-06569-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-026-06569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:02:37Z","timestamp":1774962157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-026-06569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["6569"],"URL":"https:\/\/doi.org\/10.1007\/s00705-026-06569-6","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"120"}}